경구 고형제 수탁제조 시장 : 제품 유형별, 치료 영역별, 서비스별, 최종 용도별, 세계 예측(2024-2032년)

Oral solid dosage contract manufacturing market size is expected to record 5.6% CAGR between 2024 and 2032. Lately, pharmaceutical companies are increasingly outsourcing the production of oral solid dosage forms, such as tablets, capsules, and powders to contract manufacturing organizations (CMOs) to reduce costs, improve production efficiency, and focus on core competencies like R&D activities. This is particularly prominent among small to mid-sized pharmaceutical firms looking to scale operations without investing in extensive manufacturing facilities.

The demand for generic drugs will also influence the market growth. As patents for branded drugs expire, there is a surge in the production of generic versions to meet the healthcare demands worldwide. Oral solid dosage forms are among the most prescribed medications as they offer expertise in formulation development, regulatory compliance, and manufacturing scale-up. Rising advancements in technology and quality standards to ensure consistent product quality and adherence to stringent regulatory requirements are also stimulating the market growth. For instance, in April 2024, Lupin unveiled Mirabegron extended-release tablets (25 mg) in the U.S. after approval from FDA.

The overall industry is segmented into product, type, therapeutic area, service, end-use, and region.

Based on product, the oral solid dosage contract manufacturing market from the capsules segment is expected to witness substantial growth rate through 2032 due to its increasing popularity as a preferred dosage form for both pharmaceutical companies and consumers. Capsules offer numerous advantages, including ease of swallowing, better bioavailability, and the ability to encapsulate a wide range of drug formulations, including powders, granules, and liquids. This versatility makes them ideal for a variety of therapeutic applications.

In terms of service, the oral solid dosage contract manufacturing industry from the API manufacturing segment is slated to generate notable revenue during 2024-2032. This is due to the critical role played by APIs (active pharmaceutical ingredients) in drug efficacy and formulation. As pharmaceutical companies strive to develop more effective and targeted therapies, there is an increasing demand for high-quality APIs that meet stringent regulatory standards.

Asia Pacific oral solid dosage contract manufacturing market will generate lucrative growth during 2024-2032. This is attributed to the substantial cost advantages offered by manufacturers in India and China, which provide high-quality production at lower costs compared to Western countries. The rapid expansion of the pharmaceutical industry, supported by increasing investments in healthcare infrastructure and R&D activities, is also fueling the demand for contract manufacturing services. The large and growing population, coupled with rising healthcare expenditure and the prevalence of chronic diseases, is further increasing the need for affordable and accessible medications, driving the regional industry expansion.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising adoption of CDMOs for outsourcing manufacturing activities
    • 3.2.1.2 Increasing demand for generic drugs
    • 3.2.1.3 Growing number of strategic partnerships between pharmaceutical companies and CDMOs
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Quality control challenges
    • 3.2.2.2 Intellectual property concerns
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Porter's analysis
• 3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Tablets
• 5.3 Capsules
• 5.4 Powders
• 5.5 Granules
• 5.6 Other products

Chapter 6 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Immediate release
• 6.3 Delayed release
• 6.4 Controlled release

Chapter 7 Market Estimates and Forecast, By Therapeutic Area, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Oncology
• 7.3 Cardiovascular diseases
• 7.4 Metabolic disorders
• 7.5 Neurological disorders
• 7.6 Infectious diseases
• 7.7 Gastrointestinal diseases
• 7.8 Other therapeutic areas

Chapter 8 Market Estimates and Forecast, By Service, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Drug product development
• 8.3 Fill finish product manufacturing
• 8.4 API manufacturing
• 8.5 Packaging and labelling
• 8.6 Other applications

Chapter 9 Market Estimates and Forecast, By End-Use, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 Large size companies
• 9.3 Medium & small size companies

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 10.1 Key trends
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 France
  • 10.3.4 Spain
  • 10.3.5 Italy
  • 10.3.6 Netherlands
  • 10.3.7 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 China
  • 10.4.2 Japan
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 South Korea
  • 10.4.6 Rest of Asia Pacific
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Rest of Latin America
• 10.6 Middle East and Africa
  • 10.6.1 South Africa
  • 10.6.2 Saudi Arabia
  • 10.6.3 UAE
  • 10.6.4 Rest of Middle East and Africa

Chapter 11 Company Profiles

• 11.1 Aenova Group
• 11.2 AbbVie Contract Manufacturing (AbbVie Inc.)
• 11.3 Boehringer Ingelheim International GmbH
• 11.4 Catalent, Inc.
• 11.5 Corden Pharma International
• 11.6 Jubilant Pharmova Limited
• 11.7 Lonza
• 11.8 NextPharma Technologies
• 11.9 Patheon Pharma Services (Thermo Fisher Scientific Inc.)
• 11.10 Siegfried Holding AG